Cervical priming with sublingual misoprostol vs. 15-methyl-prostaglandin F2alpha prior to surgical abortion.
OBJECTIVE
To compare the efficacy and tolerability of sublingual misoprostol with those of intramuscular 15-methyl-prostaglandin F2alpha (15-M-PG F2alpha) for cervical dilation prior to vacuum aspiration (VA) in first-trimester pregnancy termination.


METHODS
Sixty pregnant women requesting pregnancy termination between the 9th and 12th week were randomized to receive 400 microg of sublingual misoprostol or an intramuscular injection of 125 microg of 15-M-PG F2alpha 2 h prior to vacuum aspiration. Baseline cervical dilation prior to vacuum aspiration was measured using Hegar's dilators. Other variables assessed included procedure duration, intraoperative blood loss, and associated adverse effects. Patient acceptability was assessed by questionnaires completed at the time of discharge from the hospital.


RESULTS
Mean cervical dilation at vacuum aspiration was significantly greater in the misoprostol group than in the 15-M-PG F2alpha group (8.8 vs. 7.6 mm; P<0.01), and preoperative adverse effects were significantly less frequent in the sublingual misoprostol group (P<0.05). However, procedure duration and intraoperative blood loss were similar in both groups. The acceptability rates were 93.3% in the sublingual misoprostol group and 76.6% in the 15-M-PG F2alpha group, respectively; however, 6.6% patients in the sublingual misoprostol group thought that the tablets had an unpleasant taste.


CONCLUSIONS
Sublingual misoprostol appears to be an effective alternative to intramuscular 15-M-PG F2alpha for cervical dilation prior to vacuum aspiration in first trimester pregnancy. In addition, misoprostol is inexpensive and convenient to use and has higher patient acceptability rates.
Vimala
N
N
Department of Obstetrics and Gynaecology, Teaching Block, Ansari Nagar, AIIMS, New Delhi-110029, India. drvimalan@yahoo.co.in
Mittal
S
S
Dadhwal
V
V
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000028:Abortion, Induced; D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D002260:Carboprost / Q000008:administration & dosage*; D002584:Cervix Uteri / Q000187:drug effects*; D004106:Dilatation / Q000379:methods*; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage*; D011446:Prospective Studies
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol; D002260:Carboprost